19:56:03 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
Cline Scientific är verksamma inom bioteknik. Bolaget är specialiserade inom cancerdiagnostik och stamcellsterapier. Bolaget genomför utvecklingsprojekt via samarbeten med forskningsinstitutioner, där teknologin används i cellbaserade produkter och processer för att driva Life Science projekt till och genom den kliniska fasen. Bolaget har sitt huvudkontor i Göteborg och grundades under 2012.


2023-02-24 Bokslutskommuniké 2022
2022-08-26 Kvartalsrapport 2022-Q2
2022-08-17 Kvartalsrapport 2022-Q2
2022-06-10 Ordinarie utdelning CLINE B 0.00 SEK
2022-04-20 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-08-27 Kvartalsrapport 2021-Q2
2021-06-04 Ordinarie utdelning CLINE B 0.00 SEK
2021-06-03 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-08-25 Kvartalsrapport 2020-Q2
2020-02-27 Ordinarie utdelning CLINE B 0.00 SEK
2020-02-26 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-05-08 Ordinarie utdelning CLINE B 0.00 SEK
2019-05-07 Årsstämma 2019
2019-02-22 Bokslutskommuniké 2018
2018-08-10 Kvartalsrapport 2018-Q2
2018-05-03 Ordinarie utdelning CLINE B 0.00 SEK
2018-05-02 Årsstämma 2018
2018-02-23 Bokslutskommuniké 2017
2017-08-11 Kvartalsrapport 2017-Q2
2017-03-21 Ordinarie utdelning CLINE B 0.00 SEK
2017-03-20 Årsstämma 2017
2017-02-17 Bokslutskommuniké 2016
2016-11-04 Kvartalsrapport 2016-Q3
2016-08-04 Kvartalsrapport 2016-Q2
2016-05-04 Ordinarie utdelning CLINE B 0.00 SEK
2016-05-03 Kvartalsrapport 2016-Q1
2015-11-06 Kvartalsrapport 2015-Q3
2015-08-06 Kvartalsrapport 2015-Q2
2022-03-10 13:42:28

Cline Scientific AB ("Cline" or "The Company") today announces it has submitted an international PCT patent application related to the CellRACE cancer diagnostic project. 

This application is an extension to the patent application submitted to the European Patent Office, EPO announced on the 11th of March 2021. 

"CellRACE is a groundbreaking method and product in cancer diagnostics. It will simplify the choice of treatment by determining the migration potential of tumor cells earlier and more accurately. This reduces the risk of metastasis development in patients. The PCT application is the next step in establishing strong patent protection for the product developed by Cline, an important asset for the project." Says Dr. Hanne Evenbratt, Vice President - Research & Development.

After the PCT phase, the patent will enter national phases where Cline will designate the countries where Cline will pursue patents.

More about the PCT process
The PCT is an international treaty with more than 150 Contracting States, allowing applicants to file for protection in many countries simultaneously with the same filing date. A PCT, or international, application is a unified patent procedure where an application is filed with a Receiving Office, where an international search report and patentability opinion is then conducted. The PCT does not lead to a patent in itself; it is followed by designating which countries the application wants the patent to be examined. In this "national" phase, each jurisdiction designated assesses the applications and grants the patent. 

For more information, please contact:
Hanne Evenbratt, VP Research & Development
Email: hanne.evenbratt@clinescientific.com
Phone: +46 704 88 79 23